Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Insomnia Med Quviviq Now Available in Japan: Nxera/Shionogi
Nxera Pharma’s insomnia treatment Quviviq (daridorexant) hit the Japan market on December 19, with its partner Shionogi to be solely responsible for its domestic distribution and sales activities under their commercial deal announced in October. Quviviq is a dual orexin…
To read the full story
Related Article
- Nxera Pharma Eyes 50 Billion Yen in Global Revenue by 2030: CEO
November 7, 2024
- Shionogi Set to Make “QOL Diseases” Next Leg of Business: CEO
October 29, 2024
- Shionogi Sole Distributor of Nxera’s Insomnia Med in Japan
October 2, 2024
- Shionogi, Mochida Form Sales Tie-Up for Daridorexant in Japan
November 2, 2023
- Idorsia Files Insomnia Med Daridorexant in Japan: Sosei, Mochida
November 1, 2023
- Sosei to Acquire Idorsia’s Japan and Korea Arms for 65 Billion Yen
July 21, 2023
- Idorsia’s Insomnia Med Meets PIII Goal in Japan, Filing Planned for H1 2023
October 4, 2022
- Mochida, Idorsia Hook Up on Insomnia Drug in Japan
December 6, 2019
BUSINESS
- JCR’s Izcargo Reels in Conditional Approval in Kuwait
October 15, 2026
- Nxera Licenses Quviviq to Taiwan’s Synmosa in 8 APAC Markets
October 15, 2026
- Rhythm’s Imcivree Debuts in Japan for Acquired Hypothalamic Obesity
October 15, 2026
- Pfizer to Drop Avastin, Herceptin Biosimilars in Japan, Halving Portfolio
October 14, 2026
- Asahi Kasei’s Pritelivir Scores US Approval for HSV Infections
October 14, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…